NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 28, Issue 1, 2013, Pages 95-104

  Gatto, Gregory J ^a   Ao, Zhaohui ^a   Kearse, Michael G ^a   Zhou, Mei ^a   Morales, Cyndi R ^a   Daniels, Erin ^a   Bradley, Benjamin T ^a   Goserud, Matthew T ^a   Goodman, Krista B ^a   Douglas, Stephen A ^a   Harpel, Mark R ^a   Johns, Douglas G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

NADPH oxidase isoform 2; Perhexiline; Reactive oxygen species; Suramin; VAS2870

Indexed keywords

LATAMOXEF; NUCLEOTIDYLTRANSFERASE INHIBITOR; PERHEXILINE; PROTEIN KINASE C BETA; PROTEIN P47; PROTEIN P67; RAC2 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; SURAMIN; UNCLASSIFIED DRUG; VAS2870;

ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HEART PROTECTION; HUMAN; HUMAN CELL; IC 50; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

EID: 84874168194     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2011.636360     Document Type: Article

References (50)

1. Copeland RA, Harpel MR, Tummino PJ. Targeting enzyme inhibitors in drug discovery. Expert Opin Ther Targets 2007;11:967-978 (Pubitemid 47054490)
2. Babior BM. NADPH oxidase. Curr Opin Immunol 2004;16:42-47 (Pubitemid 38198116)
3. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 2007;87:245-313 (Pubitemid 46209993)
4. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S et al. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 2006;8:691-728 (Pubitemid 44043102)
5. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003;91:7A-11A. 6. Sirker A, Zhang M, Murdoch C, Shah AM. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol 2007;27:649-660 (Pubitemid 36351457)
6. Paravicini TM, Drummond GR, Sobey CG. Reactive oxygen species in the cerebral circulation: Physiological roles and therapeutic implications for hypertension and stroke. Drugs 2004;64:2143-2157 (Pubitemid 39382206)
7. Lambeth JD. Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy. Free Radic Biol Med 2007;43:332-347 (Pubitemid 46992767)
8. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002;105:293-296 (Pubitemid 34106175)
9. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H et al. Role of p47phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002;40:511-515
10. Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 2006;114:404-413 (Pubitemid 44264822)
11. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007;100:894-903 (Pubitemid 46555695)
12. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care 2008;31 Suppl 2:S170-S180
13. Cross AR, Segal AW. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim Biophys Acta 2004;1657:1-22 (Pubitemid 38823040)
14. Jaquet V, Scapozza L, Clark RA, Krause KH, Lambeth JD. Smallmolecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 2009;11:2535-2552
15. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-471
16. O'Donnell BV, Tew DG, Jones OT, England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 1993;290 (Pt 1):41-49 (Pubitemid 23081198)
17. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 1994;11:95-102
18. DeLeo FR, Nauseef WM, Jesaitis AJ, Burritt JB, Clark RA, Quinn MT. A domain of p47phox that interacts with human neutrophil flavocytochrome b558. J Biol Chem 1995;270:26246-26251 (Pubitemid 3006194)
19. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, Ishmael F et al. Inhibition of NADPH oxidase activation in endothelial cells by ortho-methoxy-substituted catechols. Endothelium 2002;9:191-203 (Pubitemid 35021589)
20. Ximenes VF, Kanegae MP, Rissato SR, Galhiane MS. The oxidation of apocynin catalyzed by myeloperoxidase: Proposal for NADPH oxidase inhibition. Arch Biochem Biophys 2007;457: 134-141 (Pubitemid 46048700)
21. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 2008;120:254-291
22. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension 2001;38:1107-1111 (Pubitemid 34252814)
23. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001;89:408-414 (Pubitemid 34132656)
24. Liu J, Ormsby A, Oja-Tebbe N, Pagano PJ. Gene transfer of NAD(P) H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ Res 2004;95:587-594 (Pubitemid 39274373)
25. Park YM, Park MY, Suh YL, Park JB. NAD(P)H oxidase inhibitor prevents blood pressure elevation and cardiovascular hypertrophy in aldosterone-infused rats. Biochem Biophys Res Commun 2004;313:812-817 (Pubitemid 38021903)
26. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I et al. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 2008;9:686-696
27. Kennedy JA, Beck-Oldach K, McFadden-Lewis K, Murphy GA, Wong YW, Zhang Y et al. Effect of the anti-anginal agent, perhexiline, on neutrophil, valvular and vascular superoxide formation. Eur J Pharmacol 2006;531:13-19 (Pubitemid 43202209)
28. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:193-204
29. Voogd TE, Vansterkenburg EL, Wilting J, Janssen LH. Recent research on the biological activity of suramin. Pharmacol Rev 1993;45:177-203 (Pubitemid 23191414)
30. Heyneman RA. Inhibition by suramin of the NADPH oxidase from horse polymorphonuclear leukocytes. Vet Res Commun 1987;11:149-157 (Pubitemid 17136873)
31. Sobey C, Chrissobolis S, Hickey H, Drummond G. Suramin inhibits NADPH oxidase activity in cerebral arteries after subarachnoid hemorrhage. FASEB J 2006;20:A725
32. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 2006;344:200-205
33. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Bäumer AT, Vantler M et al. Novel Nox inhibitor VAS2870 attenuates PDGFdependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006;71:331-341
34. Rotrosen D, Yeung CL, Katkin JP. Production of recombinant cytochrome b558 allows reconstitution of the phagocyte NADPH oxidase solely from recombinant proteins. J Biol Chem 1993;268:14256-14260. (Pubitemid 23195550)
35. Fornwald JA, Lu Q, Wang D, Ames RS. Gene expression in mammalian cells using BacMam, a modified baculovirus system. Methods Mol Biol 2007;388:95-114 (Pubitemid 350189948)
36. Abo A, Segal AW. Reconstitution of cell-free NADPH oxidase activity by purified components. Meth Enzymol 1995;256:268-278
37. Cheng G, Cao Z, Xu X, van Meir EG, Lambeth JD. Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 2001;269:131-140 (Pubitemid 32488913)
38. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J et al. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 1995;9:202-209
39. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: In vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004;286:R431-R444 (Pubitemid 38252605)
40. Nagao A, Seki M, Kobayashi H. Inhibition of xanthine oxidase by flavonoids. Biosci Biotechnol Biochem 1999;63:1787-1790. (Pubitemid 129548408)
41. Dekker LV, Leitges M, Altschuler G, Mistry N, McDermott A, Roes J et al. Protein kinase C-β contributes to NADPH oxidase activation in neutrophils. Biochem J 2000;347 Pt 1:285-289 (Pubitemid 30199068)
42. Korchak HM, Kilpatrick LE. Roles for β II-protein kinase C and RACK1 in positive and negative signaling for superoxide anion generation in differentiated HL60 cells. J Biol Chem 2001;276:8910-8917
43. Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem 1988;263: 1682-1692 (Pubitemid 18052115)
44. Kim C, Dinauer MC. Impaired NADPH oxidase activity in Rac2-deficient murine neutrophils does not result from defective translocation of p47phox and p67phox and can be rescued by exogenous arachidonic acid. J Leukoc Biol 2006;79:223-234 (Pubitemid 43054268)
45. Schuetz A, Min J, Antoshenko T, Wang CL, Allali-Hassani A, Dong A et al. Structural basis of inhibition of the human NAD+dependent deacetylase SIRT5 by suramin. Structure 2007;15:377-389 (Pubitemid 46366726)
46. Stein CA. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993;53:2239-2248 (Pubitemid 23156807)
47. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996;52:273-280 (Pubitemid 26233756)
48. Lopaschuk GD, Spafford M. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res 1989;65:378-387 (Pubitemid 19194624)
49. Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 2010;161:885-898
50. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000;36:277-281 (Pubitemid 30659851)